| Similar Articles |
|---|
 |
The Motley Fool
April 13, 2004
Nathan Slaughter |
Watching for Wily Offers General Mills urges its stock owners to reject a below-market tender offer.   |
The Motley Fool
December 8, 2006
Brian Lawler |
Mini-Tenders, Big Headaches Not all tender offers are cause for shareholder excitement. |
The Motley Fool
November 29, 2010
Rich Smith |
Don't Let This Grinch Steal Christmas Beware scam artists bearing cash. The scam in question generally goes by the name of a "mini-tender." |
The Motley Fool
August 15, 2008
Rich Smith |
Kudos for Corning LCD lord looks out for the little guy. |
The Motley Fool
June 11, 2008
Brian Lawler |
Dueling Fools: Pfizer Bear Is Pfizer ready for a comeback? The bearish opinion is that shares may be down, but the bleeding still isn't over. |
The Motley Fool
January 23, 2007
Rich Smith |
Foolish Forecast: Hungry, Hungry Caterpillar The heavy equipment maker is set to release its fiscal fourth-quarter and full-year earnings results. Investors, here is what to expect. |
The Motley Fool
January 23, 2007
Ryan Fuhrmann |
Back to the Future at Pfizer Pfizer just provided guidance for the next couple of years. The news shows that the company is willing to shake things up, but investors should remain skeptical until tangible benefits occur. |
The Motley Fool
September 9, 2011
Rich Smith |
Who Wants to Buy Travelzoo? ChaPaVe Partners, the previously unheard of firm, announces a "tactical tender offer" for 1.5 million shares of Travelzoo. |
The Motley Fool
April 19, 2006
Brian Gorman |
Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge. |
The Motley Fool
May 17, 2004
Roger Nusbaum |
Diagnosing Pfizer Can Pfizer, the pharmaceutical company, outperform the market? |
The Motley Fool
April 5, 2005
Stephen D. Simpson |
Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be? |
The Motley Fool
December 14, 2005
Steven Mallas |
Pfizer: Of Drugs and Dividends Pfizer is raising its payout. Is it a good move for the drugmaker? Investors willing to hold for years while reinvesting dividends will most likely be rewarded along the way. |
The Motley Fool
October 20, 2006
Brian Lawler |
Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth. |
The Motley Fool
July 24, 2008
Brian Lawler |
Will Pfizer Pfizzle? The drugmaker posts strong earnings, but the good times may not last. |
The Motley Fool
August 17, 2011
Ilan Moscovitz |
Pfizer Is Cheaper Than You Think Let's examine Pfizer alongside some of its peers for additional context. |
The Motley Fool
February 22, 2007
Brian Lawler |
Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today. |
The Motley Fool
January 24, 2008
Brian Lawler |
Pfiltering Through Pfizer's Year Pfizer releases its 2007 numbers, displaying year-over-year earnings growth powered by foreign currency gains. |
The Motley Fool
November 17, 2008
Rich Smith |
This Just In: Upgrades and Downgrades Bank of America analysts aren't terribly impressed with most drug companies. But they did give thumbs up to two. |
The Motley Fool
February 22, 2007
Ryan Fuhrmann |
Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008. |
Managed Care
December 2004
John Carroll |
Pfizer Touts Medicaid Data In Arguing That DM Works The pharmaceutical giant Pfizer says that its disease management program saved Florida $42 million, but a state watchdog group remains unconvinced. |
The Motley Fool
July 20, 2005
Stephen D. Simpson |
Pfizer's Long Road Back It took time for Pfizer to reach a trough and it will take time to climb out. But over the long haul this could prove to be a solid pick. |
The Motley Fool
December 18, 2008
Brian Orelli |
Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009. |
